|
By Stuart
Elliott
Madison Avenue, facing growing
legislative threats to one of the advertising industry's most lucrative
categories, is stepping up the fight to protect its freedom to pitch prescription
drugs directly to consumers.
Drug companies, agencies and
their media allies who have benefited handsomely from the flood of ads
beat back one recent measure in the House of Representatives. But advocacy
organizations on the other side of the issue vow to continue battling
to limit or even eliminate such campaigns, and one senator has introduced
legislation that would limit the pharmaceutical industry's tax deduction
for such advertising.
The
category of direct-to-consumer ads did not even exist until five years
ago. Before 1997, broad curbs prevented pharmaceutical makers from mounting
any significant efforts, and they aimed most of their spending directly
at health care professionals.
But since the Food and Drug
Administration loosened its strictures against those ads, primarily by
making it much easier to promote drugs with commercials, the category
has boomed. It has become an estimated $3
billion-a-year business for the media. That exceeds the amount
spent annually to advertise many drugs sold over the counter like analgesics
and vitamins, according to CMR, a division of Taylor Nelson Sofres that
tracks ad spending.
The spending for the direct-to-consumer
drug campaigns, which come complete with the traditional trappings of
brand advertising like celebrity endorsers, jingles, free samples and
slogans, also exceeds the yearly outlays in mainstay marketing categories
like insurance and real estate, apparel and alcoholic beverages.
Agencies are anxious to keep
that revenue flowing as they struggle to recover from the worst advertising
recession in decades. They and their clients, the drug companies, are
also eager to keep open a channel that has significantly stimulated demand
and sales.
Indeed, in a survey last month
by the Ipsos marketing research company, 25 percent of respondents said
they had been prompted by direct-to-consumer ads to call or visit a doctor
to discuss the product being advertised. Moreover, 15 percent of respondents
reported requesting the very drug that was the subject of the ad.
That is one reason opponents
castigate direct-to-consumer ads, decrying them as unfairly influencing
important health care decisions about powerful medicines that ought not
to be sold with the same sophisticated marketing ploys used to peddle
movies, soft drinks or fast food.
"The stuff done to promote
drugs works, and because it works, it's doing a disservice to the patient,"
said Sidney Wolfe, director for the health research group of Public Citizen,
an advocacy organization in Washington. "The doctors are frequently
as misled as the patients are," he added.
One doctor, J. Edward Hill
- the new chairman of the American Medical Association in Chicago - offered
another complaint. "We have no policy that opposes direct-to-consumer
advertising, mainly because of freedom-of-speech issues," Dr. Hill
said. "However, we do have some big concerns about advertising getting
in the middle of the patient-physician relationship.
"It's sometimes even creating
an adversarial relationship," he added, "when the patient insists
on an advertised medicine but the doctor believes it's not the best or
most effective medicine."
The agencies are being joined
by lobbyists for media that would lose ad revenue if Congress tightened
rules for direct-to-consumer ads. At one time, some magazine and newspaper
publishers perceived television and radio as rivals for ad revenue from
makers of prescription drugs, but the media are now working together.
New
York Times July 12, 2002
|